BiotechTube

Bimatoprost Implant System + Timolol Maleate Ophthalmic Solution, 0.5%

Phase 3Recruiting
1 views this week 0 watching⚡ Active🔬Featured in Small-Cap Pipeline Watch
Interest: 41/100
41
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Cataract

Conditions

Cataract, Glaucoma, Ocular Hypertension

Trial Timeline

Oct 28, 2025 → May 31, 2031

NCT ID
NCT07218796

About Bimatoprost Implant System + Timolol Maleate Ophthalmic Solution, 0.5%

Bimatoprost Implant System + Timolol Maleate Ophthalmic Solution, 0.5% is a phase 3 stage product being developed by SpyGlass Pharma for Cataract. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07218796. Target conditions include Cataract, Glaucoma, Ocular Hypertension.

What happened to similar drugs?

10 of 19 similar drugs in Cataract were approved

Approved (10) Terminated (3) Active (7)
🔄ISV-305Sun PharmaceuticalPhase 3
🔄ISV-305Sun PharmaceuticalPhase 3
🔄DE-108 + Levofloxacin 0.5%Santen PharmaceuticalPhase 3
✅Prednisolone acetateNovartisApproved
✅Omidria + Dextenza (dexamethasone ophthalmic insert) 0.4mg + Dexycu, 9% Intraocular Suspension + Prednisolone Acetate 1%Ocular TherapeutixApproved
✅Dextenza 0.4Mg Ophthalmic InsertOcular TherapeutixApproved
🔄Dextenza Ophthalmic Insert + Prednisolone acetate ophthalmic suspension USP 1%Ocular TherapeutixPhase 3

Hype Score Breakdown

Clinical
17
Activity
15
Company
9
Novelty
0
Community
0

Clinical Trials (2)

NCT IDPhaseStatus
NCT07218796Phase 3Recruiting
NCT07218783Phase 3Recruiting

Competing Products

20 competing products in Cataract

See all competitors
ProductCompanyStageHype Score
ISV-305Sun PharmaceuticalPhase 3
40
ISV-303 + Bromday™Sun PharmaceuticalPhase 2
35
ISV-305Sun PharmaceuticalPhase 3
40
DE-108 + Levofloxacin 0.5%Santen PharmaceuticalPhase 3
40
Prednisolone acetateNovartisApproved
43
Omidria + Dextenza (dexamethasone ophthalmic insert) 0.4mg + Dexycu, 9% Intraocular Suspension + Prednisolone Acetate 1%Ocular TherapeutixApproved
37
Dextenza 0.4Mg Ophthalmic InsertOcular TherapeutixApproved
37
Dextenza Ophthalmic Insert + Prednisolone acetate ophthalmic suspension USP 1%Ocular TherapeutixPhase 3
34
Dextenza 0.4Mg Ophthalmic Insert + Prednisolone Acetate 1% Ophthalmic Suspension [PRED FORTE]Ocular TherapeutixPhase 2/3
24
Dexamethasone 0.4 MG [Dextenza]Ocular TherapeutixApproved
37
Dextenza 0.4Mg Ophthalmic Insert + Topical prednisolone acetateOcular TherapeutixApproved
37
Dextenza 0.4mg intracanalicular Insert + Durezol 0.05% Ophthalmic EmulsionOcular TherapeutixApproved
29
DexycuEyePoint PharmaceuticalsPhase 3
26
Dexycu + Standard of Care post operative eye drops (steroid, antibiotic, NSAID)EyePoint PharmaceuticalsApproved
37
DexycuEyePoint PharmaceuticalsPhase 3
26
DEXYCU (dexamethasone intraocular suspension) 9%.EyePoint PharmaceuticalsPre-clinical
20
Dexamethasone + Prednisolone Acetate OphthalmicEyePoint PharmaceuticalsApproved
44
Bimatoprost Implant System (High Dose) + Bimatoprost Implant System (Low Dose) + Timolol Maleate Ophthalmic Solution, 0.5%SpyGlass PharmaPhase 1/2
30
Bimatoprost Implant System + Timolol Maleate Ophthalmic Solution, 0.5%SpyGlass PharmaPhase 3
41
OMS302 + OMS302-PE + VehicleOmeros CorporationPhase 1/2
26